Shire and Shionogi Announce Positive Topline Results for INTUNIV® (guanfacine hydrochloride prolonged release) Evaluated in Phase 3 Clinical Trial in Adults with ADHD
(World News Science)

Topline results revealed the study met its primary endpoint for INTUNIV (4 to 6 mg) administered once daily, indicating superiority over placebo in ADHD symptom improvement Results also showed improvement over placebo in patients` global functioning Zug, Switzerland - September 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) and its partner in Japan, Shionogi & Co., Ltd, announced that a Phase 3 study evaluating INTUNIV (guanfacine hydrochloride prolonged release) in adult patients with attention deficit hyperactivity disorder (ADHD) in Japan has positive topline results, and the study met the primary endpoint. This is the first clinical trial evaluating INTUNIV in adult patients (18 years old...